Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8102067rdf:typepubmed:Citationlld:pubmed
pubmed-article:8102067lifeskim:mentionsumls-concept:C0001924lld:lifeskim
pubmed-article:8102067lifeskim:mentionsumls-concept:C0304925lld:lifeskim
pubmed-article:8102067lifeskim:mentionsumls-concept:C0237868lld:lifeskim
pubmed-article:8102067lifeskim:mentionsumls-concept:C1185738lld:lifeskim
pubmed-article:8102067lifeskim:mentionsumls-concept:C0005064lld:lifeskim
pubmed-article:8102067lifeskim:mentionsumls-concept:C0036679lld:lifeskim
pubmed-article:8102067lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:8102067lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:8102067lifeskim:mentionsumls-concept:C0008565lld:lifeskim
pubmed-article:8102067lifeskim:mentionsumls-concept:C2745888lld:lifeskim
pubmed-article:8102067lifeskim:mentionsumls-concept:C1516451lld:lifeskim
pubmed-article:8102067lifeskim:mentionsumls-concept:C1514623lld:lifeskim
pubmed-article:8102067lifeskim:mentionsumls-concept:C0599473lld:lifeskim
pubmed-article:8102067pubmed:issue2lld:pubmed
pubmed-article:8102067pubmed:dateCreated1993-9-9lld:pubmed
pubmed-article:8102067pubmed:abstractTextSpecific ligand markers for the various binding sites of human serum albumin (HSA) have been described in the literature. Some of these markers (medium chain fatty acids, warfarin, digoxin, and bilirubin) were used as mobile phase modifiers. Using a high performance liquid chromatographic (HPLC) column containing HSA as stationary phase, their influence was investigated on the separation in this phase of the enantiomers of three benzodiazepines (temazepam, oxazepam, and lorazepam). Displacement effects were observed with medium chain fatty acids. This influence was proportional to the chain length and to the concentration of acid. Allosteric cooperative effects were noted with digoxin for the three benzodiazepines. Both displacement and cooperative effects were observed with warfarin. Stereoselectivity was decreased for temazepam and oxazepam and increased for lorazepam.lld:pubmed
pubmed-article:8102067pubmed:languageenglld:pubmed
pubmed-article:8102067pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102067pubmed:citationSubsetIMlld:pubmed
pubmed-article:8102067pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102067pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102067pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102067pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102067pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102067pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102067pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8102067pubmed:statusMEDLINElld:pubmed
pubmed-article:8102067pubmed:issn0899-0042lld:pubmed
pubmed-article:8102067pubmed:authorpubmed-author:UzanSSlld:pubmed
pubmed-article:8102067pubmed:authorpubmed-author:WainerI WIWlld:pubmed
pubmed-article:8102067pubmed:authorpubmed-author:FarinottiRRlld:pubmed
pubmed-article:8102067pubmed:authorpubmed-author:GimenezFFlld:pubmed
pubmed-article:8102067pubmed:authorpubmed-author:ChossonEElld:pubmed
pubmed-article:8102067pubmed:issnTypePrintlld:pubmed
pubmed-article:8102067pubmed:volume5lld:pubmed
pubmed-article:8102067pubmed:ownerNLMlld:pubmed
pubmed-article:8102067pubmed:authorsCompleteYlld:pubmed
pubmed-article:8102067pubmed:pagination71-7lld:pubmed
pubmed-article:8102067pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8102067pubmed:meshHeadingpubmed-meshheading:8102067-...lld:pubmed
pubmed-article:8102067pubmed:meshHeadingpubmed-meshheading:8102067-...lld:pubmed
pubmed-article:8102067pubmed:meshHeadingpubmed-meshheading:8102067-...lld:pubmed
pubmed-article:8102067pubmed:meshHeadingpubmed-meshheading:8102067-...lld:pubmed
pubmed-article:8102067pubmed:meshHeadingpubmed-meshheading:8102067-...lld:pubmed
pubmed-article:8102067pubmed:meshHeadingpubmed-meshheading:8102067-...lld:pubmed
pubmed-article:8102067pubmed:meshHeadingpubmed-meshheading:8102067-...lld:pubmed
pubmed-article:8102067pubmed:meshHeadingpubmed-meshheading:8102067-...lld:pubmed
pubmed-article:8102067pubmed:meshHeadingpubmed-meshheading:8102067-...lld:pubmed
pubmed-article:8102067pubmed:meshHeadingpubmed-meshheading:8102067-...lld:pubmed
pubmed-article:8102067pubmed:meshHeadingpubmed-meshheading:8102067-...lld:pubmed
pubmed-article:8102067pubmed:year1993lld:pubmed
pubmed-article:8102067pubmed:articleTitleInfluence of specific albumin ligand markers used as modifiers on the separation of benzodiazepine enantiomers by chiral liquid chromatography on a human serum albumin column.lld:pubmed
pubmed-article:8102067pubmed:affiliationUnité de Dosage de Médicaments, Hôpital Pitié Salpetriere, Paris, France.lld:pubmed
pubmed-article:8102067pubmed:publicationTypeJournal Articlelld:pubmed